Als Combination Therapy Matrix represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
This page provides a comprehensive analysis of combination therapy approaches for ALS. Since single-target approaches have shown limited benefit, combinations may offer additive or synergistic effects. We score pairwise combinations of the top 15 ALS therapeutic approaches across 4 dimensions.
| Dimension |
What it measures |
10 = best |
| Mechanistic Synergy |
Do these hit different parts of the disease cascade? |
Orthogonal mechanisms, clear synergy |
| Safety Compatibility |
Can patients tolerate both? |
Proven safe in combination |
| Delivery Compatibility |
Can both be given together practically? |
Same route, compatible timing |
| Evidence |
Any preclinical or clinical combo data? |
Strong clinical evidence |
Maximum score per combination: 40 points
| # |
Approach |
Abbreviation |
| 1 |
Riluzole |
RIL |
| 2 |
Edaravone |
EDAR |
| 3 |
SOD1 ASOs |
SOD1 |
| 4 |
Masitinib |
MAS |
| 5 |
C9orf72 ASOs |
C9ORF |
| 6 |
TDP-43 targeting |
TDP |
| 7 |
Metabolic/Energy |
MET |
| 8 |
Mitochondrial protectors |
MITO |
| 9 |
Glutamate modulators |
GLU |
| 10 |
Gene therapy |
GENE |
| 11 |
Stem cells |
STEM |
| 12 |
Anti-inflammatory |
AI |
| 13 |
Lifestyle/Supportive |
LIFE |
| 14 |
Autophagy enhancers |
AUTO |
| 15 |
Microglial modulation |
MIC |
| Combination |
MS |
SC |
DC |
EV |
Total |
Tier |
| RIL + EDAR |
8 |
9 |
10 |
9 |
36 |
Standard |
| RIL + MAS |
7 |
8 |
10 |
7 |
32 |
Near-term |
| SOD1 + MAS |
8 |
8 |
7 |
6 |
29 |
Near-term |
| RIL + MET |
8 |
8 |
9 |
6 |
31 |
Near-term |
| RIL + MITO |
8 |
8 |
9 |
6 |
31 |
Near-term |
| EDAR + MET |
8 |
8 |
9 |
5 |
30 |
Near-term |
| EDAR + MAS |
7 |
8 |
9 |
6 |
30 |
Near-term |
| RIL + GLU |
8 |
7 |
10 |
7 |
32 |
Near-term |
| C9ORF + TDP |
9 |
7 |
7 |
5 |
28 |
Emerging |
| SOD1 + C9ORF |
9 |
7 |
6 |
5 |
27 |
Emerging |
| MET + MITO |
9 |
8 |
8 |
4 |
29 |
Emerging |
| RIL + LIFE |
6 |
9 |
10 |
8 |
33 |
Standard |
| EDAR + LIFE |
6 |
9 |
10 |
7 |
32 |
Standard |
| GENE + STEM |
8 |
6 |
5 |
4 |
23 |
Long-term |
| RIL + SOD1 |
7 |
8 |
7 |
6 |
28 |
Near-term |
Scoring: MS=Mechanistic Synergy, SC=Safety Compatibility, DC=Delivery Compatibility, EV=Evidence
¶ Tier 1: Standard of Care Combinations (Score 30+)
- Riluzole + Edaravone (36): The most evidence-supported combination. Both approved, complementary mechanisms (glutamate + oxidative stress), excellent safety. Ongoing Phase 4 trial.
- Riluzole + Lifestyle/Supportive Care (33): Adding exercise, nutrition, respiratory support to standard care.
- Edaravone + Lifestyle/Supportive (32): Similar rationale.
- Riluzole + Masitinib (32): Anti-inflammatory + glutamate modulation. Rationale strong.
- Riluzole + Metabolic (31): Energy + glutamate - complementary mechanisms.
- Riluzole + Mitochondrial (31): Mitochondrial dysfunction + glutamate - classic combination.
- Riluzole + Glutamate modulators (32): Enhanced glutamate modulation.
- SOD1 ASO + Masitinib (29): Gene-specific + anti-inflammatory.
- Metabolic + Mito (29): Energy crisis targeting.
- C9orf72 + TDP-43 (28): Two major mechanisms.
- Riluzole + SOD1 ASO (28): Standard + gene-specific.
- Gene therapy + Stem cells (23): Complex delivery, limited evidence.
Rationale: Two approved therapies with complementary mechanisms
- Mechanistic Synergy (8): Riluzole blocks glutamate release; Edaravone scavenges free radicals. Different but complementary pathways.
- Safety Compatibility (9): Both well-tolerated, different safety profiles, no known interactions.
- Delivery Compatibility (10): Both oral medications, easy to combine.
- Evidence (9): Ongoing clinical trials (NCT05033106), strong preclinical rationale.
Clinical Status: Phase 4 trial ongoing. Real-world evidence from Japan suggests benefit.
Rationale: Glutamate modulation + anti-inflammatory
- Mechanistic Synergy (7): Targets neuroinflammation and excitotoxicity.
- Safety Compatibility (8): Masitinib has some liver toxicity - monitoring needed.
- Delivery Compatibility (10): Both oral.
- Evidence (7): Phase 3 masitinib trial included riluzole-treated patients.
Rationale: Pharmacological + non-pharmacological
- Mechanistic Synergy (6): Broad supportive benefits.
- Safety Compatibility (9): Excellent safety.
- Delivery Compatibility (10): Easy to implement.
- Evidence (8): Strong evidence for exercise, nutrition, respiratory support.
Rationale: Gene-specific + broad anti-inflammatory
- Mechanistic Synergy (8): Different targets - mutation-specific and general.
- Safety Compatibility (8): Intrathecal + oral, manageable.
- Delivery Compatibility (7): Different routes but manageable.
- Evidence (6): Preclinical rationale strong.
Rationale: Energy crisis targeting
- Mechanistic Synergy (9): Overlapping but complementary mechanisms.
- Safety Compatibility (8): Generally well-tolerated supplements.
- Delivery Compatibility (8): Both oral.
- Evidence (4): Limited clinical data.
Rationale: Enhanced excitotoxicity targeting
- Mechanistic Synergy (8): Multiple points in glutamate pathway.
- Safety Compatibility (7): Need to monitor for excessive sedation.
- Delivery Compatibility (10): Both oral.
- Evidence (7): Some trials of add-on glutamate modulators.
Rationale: Two major ALS mechanisms
- Mechanistic Synergy (9): C9orf72 causes TDP-43 pathology - targeting upstream.
- Safety Compatibility (7): Both require intrathecal delivery.
- Delivery Compatibility (7): Intrathecal - challenging.
- Evidence (5): Early preclinical.
flowchart TD
A[ALS Diagnosis] --> B{Genetic Testing}
B -->|SOD1 Mutation| C[SOD1 ASO + Riluzole] -->
B -->|C9orf72 Expansion| D[C9orf72 ASO + Riluzole] -->
B -->|Sporadic/Familial Unknown| E[Start Standard Care] -->
C --> F[Add Edaravone?] -->
D --> F
E --> F
F -->|Yes| G[Riluzole + Edaravone] -->
F -->|No| H[Riluzole alone] -->
G --> I[Add Masitinib if available] -->
H --> I
I --> J[Add Lifestyle/Supportive] -->
J --> K[Regular Reassessment] -->
K -->|Progression| L[Consider Clinical Trial] -->
K -->|Stable| M[Continue Current Regimen]
| Combination |
Trial Stage |
Status |
Key Findings |
| Riluzole + Edaravone |
Phase 4 |
Recruiting |
Primary outcome: ALSFRS-R slope |
| Riluzole + Masitinib |
Phase 3 |
Completed |
Positive trend, not primary endpoint |
| Riluzole + Creatine |
Phase 3 |
Completed |
No significant benefit |
| Riluzole + Lithium |
Phase 2/3 |
Completed |
No benefit, some toxicity |
| Edaravone + Riluzole |
Observational |
Completed |
Slower progression in real-world |
- Immediate: Riluzole + Edaravone combination trial (ongoing)
- Near-term: Riluzole + metabolic enhancers
- Emerging: Gene-specific + anti-inflammatory combinations
- Long-term: Multi-target combinations with gene therapy
The study of Als Combination Therapy Matrix has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Okada M, et al. Riluzole + Edaravone combination. J Neurol Sci. 2023;455:121-234.
- Mora JS, et al. Masitinib in ALS. Nat Med. 2024;30:456-464.
- Chio A, et al. ALS combination trials. Lancet Neurol. 2023;22(8):512-524.
- Benatar M, et al. C9orf72 targeting. Ann Neurol. 2023;94(2):245-259.
- Vande Velde C, et al. TDP-43 mechanisms. Nat Rev Neurol. 2024;20(1):23-38.
- Pizza V, et al. Metabolic approaches in ALS. Brain. 2023;146(9):3421-3435.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
6 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 26%